Search Result

Results for "

IRAK4 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	IRAK (94) Apoptosis (15) Autophagy (3) c-Met/HGFR (3) CCR (1) CDK (1) CXCR (1) Cyclic GMP-AMP Synthase (1) Endogenous Metabolite (2) Enolase (1) Environmental Pollutants (1) ERK (1) FLT3 (11) Glucocorticoid Receptor (4) IFNAR (5) Interleukin Related (12) JAK (1) Ligands for Target Protein for PROTAC (2) MAP3K (2) MAP4K (1) MyD88 (9) NF-κB (17) p38 MAPK (4) Pim (1) PROTACs (15) Reactive Oxygen Species (ROS) (2) Reference Standards (8) STAT (1) TGF-β Receptor (4) TNF Receptor (5) Toll-like Receptor (TLR) (8) Trk Receptor (1)
By Research Areas:	Cancer (52) Infection (6) Inflammation/Immunology (75) Metabolic Disease (1) Neurological Disease (5)
Click Chemistry:	PROTAC Synthesis (1)
Oligonucleotides:	CpG ODNs (3)

110

Inhibitors & Agonists

Click Chemistry

Oligonucleotides

Targets Recommended: IRAK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145483

KT-474 1 Publications Verification KYM-001; PROTAC IRAK4 degrader-7	PROTACs IRAK Apoptosis	Cancer
KT-474 (KYM-001; PROTAC IRAK4 degrader-7) is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL. KT-474 is a click chemistry reagent, containing an alkyne group, which can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing azide groups .

HY-103490

Takinib 25+ Cited Publications EDHS-206	MAP3K Apoptosis	Infection Inflammation/Immunology Cancer
Takinib (EDHS-206) is an orally active and selective TAK1 inhibitor (IC₅₀=9.5 nM), more than 1.5 log more potent than the second and third ranked targets, IRAK4 (120 nM) and IRAK1 (390 nM), respectively. Takinib is an inhibitor of autophosphorylated TAK1 that non-competitively binds within the ATP binding pocket. Takinib induces apoptosis following TNFα stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. Takinib is also a P. falciparum protein kinase 9 (PfPK9) inhibitor (K_D(app) of 0.46 μM) .

HY-19836

Zimlovisertib 5+ Cited Publications PF-06650833	IRAK	Inflammation/Immunology
Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC₅₀s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. Zimlovisertib is used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas .

HY-14721

Tepotinib 5+ Cited Publications EMD-1214063	c-Met/HGFR Autophagy	Cancer
Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation and induces autophagy. Tepotinib has antitumor effects .

HY-18992

AS2444697	IRAK	Inflammation/Immunology
AS2444697 is an orally active *IRAK-4* inhibitor with an IC₅₀ of 21 nM . AS2444697 potently inhibits human and rat IRAK-4 activity. AS2444697 exhibits renoprotective effects through anti-inflammatory action .

HY-50937

ST 2825 Maximum Cited Publications 70 Publications Verification	MyD88	Inflammation/Immunology
ST 2825 is a specific MyD88 dimerization inhibitor. ST2825 interferes with recruitment of IRAK1 and IRAK4 by MyD88, causing inhibition of IL-1β-mediated activation of NF-κB transcriptional activity .

HY-153368

Zomiradomide KT-413	PROTACs IRAK NF-κB IFNAR	Cancer
Zomiradomide is an orally active PROTAC degrader for *IRAK4* (DC₅₀=6 nM), thereby inhibiting the NF-κB signaling pathway. Zomiradomide acts also as a molecular glue, recruiting Ikaros and Aiolos, and mediating their degradation (DC₅₀ for Ikaros is 1 nM), thereby activating the type I IFN signaling pathway . (Pink: target protein ligand PROTAC IRAK4 ligand-5 (HY-168311), Blue: E3 ligase ligand Thalidomide-4-Br (HY-W039116), Black: linker (HY-168313))

HY-139374

Zabedosertib 2 Publications Verification BAY 1834845	IRAK	Inflammation/Immunology
Zabedosertib (BAY 1834845) is a selective, orally active *IRAK4* inhibitor with immunomodulatory potential, IC₅₀ is 3.55 nM. IRAK4 is a protein kinase involved in signaling innate immune responses from Toll-like receptors . Zabedosertib exhibits anti-inflammatory property against IL-β, LPS (HY-D1056) and Imiquimod (HY-B1080) induced inflammation .

HY-103017A

JH-X-119-01 5+ Cited Publications	IRAK	Infection Inflammation/Immunology Cancer
JH-X-119-01 is a potent and selective interleukin-1 receptor-associated kinases 1 (IRAK1) inhibitor. JH-X-119-01 ameliorates LPS-induced sepsis in mice . JH-X-119-01 inhibits IRAK1 biochemically with an apparent IC₅₀ of 9 nM while exhibiting no inhibition of IRAK4 at concentrations up to 10 μM .

HY-111101

AZ1495	IRAK	Cancer
AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 *(IRAK4)* inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC₅₀ values of 0.005 μM and 0.023 μM, respectively. AZ1495 has IRAK4 inhibition with a K_d value of 0.0007 μM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .

HY-160487

KME-2780	IRAK Apoptosis	Cancer
KME-2780 is the orally active inhibitor for *IRAK1* and *IRAK4* with IC₅₀s of 19 nM and 0.5 nM. KME-2780 can be used for research of dysregulation of innate immune signaling and hematologic malignancies .

HY-114181

IRAK4-IN-4 1 Publications Verification	IRAK Cyclic GMP-AMP Synthase	Inflammation/Immunology
IRAK4-IN-4 (Compound 15) is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, with an IC₅₀ of 2.8 nM. IRAK4-IN-4 also inhibits cyclic GMP-AMP synthase (cGAS) with an IC₅₀ of 2.1 nM. IRAK4-IN-4 can be used for research of autoimmune diseases .

HY-101922

IRAK4-IN-1	IRAK	Inflammation/Immunology
IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC₅₀ of 7 nM.

HY-135317

Emavusertib 5+ Cited Publications CA-4948	IRAK Apoptosis FLT3 NF-κB MyD88	Inflammation/Immunology Cancer
Emavusertib is an orally active inhibitor for IRAK4 (IC₅₀=57 nM) and FLT3. Emavusertib inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib exhibits antitumor activity in mouse model

HY-138742

HPK1-IN-7	MAP4K	Cancer
HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC₅₀=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1 .

HY-109585

IRAK4-IN-7	IRAK	Inflammation/Immunology Cancer
IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment .

HY-13275

IRAK inhibitor 1	IRAK	Inflammation/Immunology
IRAK inhibitor 1 is a potent *IRAK-4* inhibitor with IC₅₀ of 216 nM, is poorly active against JNK-1 and JNK-2 with IC₅₀ of 3.801 μM, and >10 μM, respectively.

HY-77048

IRAK-4 protein kinase inhibitor 2	IRAK	Inflammation/Immunology
IRAK-4 protein kinase inhibitor 2 (compound 1) is a potent inhibitor of interleukin-1 (IL-1) receptor-associated kinase-4 (IRAK-4), with an IC₅₀ of 4 μM. IRAK-4 protein kinase inhibitor 2 can be used for the research of inflammatory and immune-related conditions or disorders .

HY-147264

Edecesertib GS-5718	IRAK	Inflammation/Immunology
Edecesertib (GS-5718) is a selective, potent, orally active *IRAK-4* inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research .

HY-153224

GLPG2534	IRAK	Inflammation/Immunology
GLPG2534 is an orally active and selective *IRAK4* inhibitor, with IC₅₀ values of 6.4 nM and 3.5 nM for human and mouse IRAK4. GLPG2534 can be used for the research of inflammatory skin diseases .

HY-148238

GNE-2256	IRAK	Inflammation/Immunology
GNE-2256 (molecule 19), a chemical probe, is an orally active *IRAK4* (Interleukin 1 receptor associated kinase 4) inhibitor (IRAK4 K_i=1.4 nM; IL-6 IC₅₀=190 nM) .

HY-123854

PF-06426779	IRAK	Inflammation/Immunology
PF-06426779 is a potent and selective inhibitor of interleukin 1 receptor associated kinase 4 (IRAK4), with an IC₅₀ of 0.3 nM .

HY-174455

APH02174	PROTACs IRAK Interleukin Related	Inflammation/Immunology
APH02174 is a highly selective and orally active IRAK4 PROTAC degrader with the DC₅₀ of 4.01 nM in THP-1 cells. APH02174 blocks inflammatory signals by inhibiting IL-6 release. APH02174 can be used for research on inflammatory conditions such as psoriasis vulgaris and rheumatoid arthritis .

HY-14721R

Tepotinib (Standard) EMD-1214063 (Standard)	Reference Standards c-Met/HGFR Autophagy	Cancer
Tepotinib (Standard) is the analytical standard of Tepotinib. This product is intended for research and analytical applications. Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation. Tepotinib has antitumor effects .

HY-W014223

2,4′-Dihydroxybenzophenone Ultraviolet absorber UV-0	Environmental Pollutants Toll-like Receptor (TLR) NF-κB Reactive Oxygen Species (ROS) MyD88 IRAK	Inflammation/Immunology
2,4′-Dihydroxybenzophenone (Ultraviolet absorber UV-0) occupies the hydrophobic pocket of MD2 and blocks the dimerization of TLR4. 2,4′-Dihydroxybenzophenone inhibits the LPS induced mtROS production, and LPS induced inflammatory response by downregulating pro-inflammatory mediators and decreasing the expression of MyD88, p-IRAK4, and NF-κB. 2,4′-Dihydroxybenzophenone is also a UV absorber .

HY-150735

IRAK4-IN-20	IRAK	Inflammation/Immunology
IRAK4-IN-20 (Compound BAY-1834845) is an orally active *IRAK4* inhibitor with an IC₅₀ of 3.55 nM. IRAK4-IN-20 can be used for acute respiratory distress syndrome (ARDS) research .

HY-151363

IRAK4-IN-21	IRAK	Inflammation/Immunology
IRAK4-IN-21 (compound 17) is an orally active, potent and selective *IRAK4* inhibitor with IC₅₀ values of 5 and 56 nM for *IRAK4* and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.17 μM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .

HY-151365

IRAK4-IN-22	IRAK	Inflammation/Immunology
IRAK4-IN-22 (compound 18) is an orally active, potent and selective *IRAK4* inhibitor with IC₅₀ values of 3 and 17 nM for *IRAK4* and TAK1, respectively. IRAK4-IN-21 effectively inhibits IL-23 production (IC₅₀=0.10 µM) and can be used in studies of autoimmune diseases such as plaque psoriasis and psoriatic arthritis .

HY-146112

IRAK4-IN-14	IRAK	Cancer
IRAK4-IN-14 (compound 28) is a potent, selective and orally active *IRAK4* inhibitor with an IC₅₀ of 0.003 µM. IRAK4-IN-14 shows good PK parameters in rats and mouse. IRAK4-IN-14 shows synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL in combination with Acalabrutinib .

HY-179094

PSP-0119	PROTACs IRAK NF-κB Enolase	Inflammation/Immunology Cancer
PSP-0119 is a highly efficient and effective PROTAC degrader targeting *IRAK4* (IC₅₀ = 2.83 nM). PSP-0119 can inhibit *IRAK4* kinase activity, NF-κβ activity, and IL-1β-induced IRAK4 phosphorylation. PSP-0119 degrades IRAK4 in FLT3-mutant AML cell lines, sparing FLT3-wild-type AML cells, FLT3-wild-type samples, and normal bone marrow. PSP-0119 downregulates alpha-enolase (eNOS) of MOLM-13 cells. PSP-0119 can be used for the study of Acute Myeloid Leukemia (AML) .

HY-159953

IRAK1/4/pan-FLT3 Kinase-IN-1	IRAK FLT3	Inflammation/Immunology Cancer
IRAK1/4/pan-FLT3 Kinase-IN-1 is an orally active, potent and selective *IRAK/pan-FLT3* kinase inhibitor with IC₅₀s of 5 nM, 0.6 nM and <0.5 nM against IRAK1, IRAK4 and FLT3, respectively. IRAK1/4/pan-FLT3 Kinase-IN-1 can be used for research on AML .

HY-134911

HS-243	IRAK CDK	Inflammation/Immunology Cancer
HS-243 is a potent and selective *IRAK-4* and *IRAK-1* inhibitor, with IC₅₀ values of 20 and 24 nM. HS-243 shows minimal TAK1 (transforming growth factor β-activated kinase 1) inhibition activity, with a IC₅₀ of 0.5 μM. HS-243 shows anti-inflammatory and anticancer activity .

HY-162359

BIO-7488	IRAK	Neurological Disease Inflammation/Immunology
BIO-7488 is an orally active, selective and blood-brain barrier permeable *IRAK4* inhibitor, with an IC₅₀ value of 0.5 nM. BIO-7488 inhibits the production of pro-inflammatory cytokines (IL-1β, TNFα, IL-6) and demonstrates anti-inflammatory effects in both LPS (HY-D1056) and distal hypoxic-middle cerebral artery occlusion (DH-MCAO) ischemic stroke model. BIO-7488 can be used for the study of neuroinflammatory-related diseases, particularly ischemic stroke .

HY-153673

PROTAC IRAK4 degrader-8	IRAK PROTACs	Cancer
PROTAC IRAK4 degrader-8 (Compound 2) is a PROTAC *IRAK4* degrader (IC₅₀: 15.5 nM). PROTAC IRAK4 degrader-8 degrades IRAK4 in THP-1 cells (DC₅₀: 1.8 nM)。PROTAC IRAK4 degrader-8 also inhibits L-6 production in human whole blood and LPS-induced human PBMC cells, with IC₅₀s of 246 nM and 2.2 nM respectively .

HY-130253

IRAK4-IN-6	IRAK	Cancer
IRAK4-IN-6 is an orally efficacious and selective *IRAK4* inhibitor with an IC₅₀ of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma .

HY-175022

PROTAC IRAK4 degrader-13	PROTACs IRAK Toll-like Receptor (TLR) Interleukin Related	Inflammation/Immunology
PROTAC IRAK4 degrader-13 (Degrader 1) is a selective *IRAK4* PROTAC degrader with DC₅₀s of 0.86 and 1.1 nM for monocytes and lymphocytes in PBMCs, respectively. PROTAC IRAK4 degrader-13 significantly induces TIR signal activation, and inhibits the expression of circulating proinflammatory cytokines in Imiquimod (HY-B0180) induced psoriasis mice model. PROTAC IRAK4 degrader-13 can be used for TLR- and IL-1R-driven driven neutrophilic inflammation diseases like hidradenitis suppurativa (HS) and atopic dermatitis (AD) research . Pink: IRAK4 ligand; Blue: E3 ligase ligand; Black: linker

HY-148276

KTX-497	PROTACs IRAK	Cancer
KTX-497 is an *IRAK4* PROTAC degrader with a DC₅₀ value of 3 nM. KTX-497 can be used for the research of oncology ^[1].(Pink:IRAK4 inhibitor (HY-150735); Black: linker; Blue: CRBN Ligand (HY-10984))

HY-131903

HS271	IRAK	Inflammation/Immunology
HS271 is a highly potent, orally active and selective *IRAK4* inhibitor, with an IC₅₀ of 7.2 μM. HS271 exhibits superior enzymatic and cellular activities, as well as excellent pharmacokinetic properties .

HY-14721A

Tepotinib hydrochloride EMD-1214063 hydrochloride	c-Met/HGFR Autophagy	Cancer
Tepotinib (EMD-1214063) hydrochloride is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC₅₀ of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib hydrochloride inhibits c-Met phosphorylation and induces autophagy. Tepotinib hydrochloride has antitumor effects .

HY-178012

GLPG4471	IRAK TNF Receptor	Inflammation/Immunology
GLPG4471 is a selective and orally active *IRAK4* inhibitor with an IC₅₀ of 1.7 nM. GLPG4471 exhibits potent inhibition of cytokine (TNFα and IFNα) secretion in cellular and whole blood phenotypic assays. GLPG4471 displays significant activity in a mouse model of collagen-induced arthritis. GLPG4471 can be used for the study of arthritis .

HY-13278

IRAK inhibitor 4 1 Publications Verification	IRAK	Inflammation/Immunology
IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4(IRAK4) inhibitor.

HY-13280

IRAK inhibitor 6	IRAK	Inflammation/Immunology
IRAK inhibitor 6 is an inhibitor of interleukin-1 receptor associated kinase 4 (IRAK-4) with IC₅₀ of 160 nM.

HY-177515

IRAK4 modulator-2	IRAK STAT JAK NF-κB	Inflammation/Immunology
IRAK4 modulator-2 (Compound 5) is a selective dual Interleukin-1 Receptor Associated Kinase 4 (IRAK4) and *IRAK1* inhibitor with IC₅₀ values of 0.005 μM and 0.97 μM, erespectively. IRAK4 modulator-2 blocks IRAK-mediated signaling pathways (e.g., JAK-STAT, NF-κB pathways), reduces the production of pro-inflammatory cytokines (e.g., IL-1, TNF), and exerts anti-inflammatory activity. IRAK4 modulator-2 is promising for research of autoimmune diseases and inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel disease .

HY-179095

UR241-2	Ligands for Target Protein for PROTAC IRAK NF-κB p38 MAPK	Cancer
UR241-2 is an *IRAK4* inhibitor. UR241-2 suppresses IL-1–induced *IRAK1/4* signaling, NF-κβ activation, and phosphorylation of p65 and p38. UR241-2 selectively inhibits leukemia stem cell clonogenicity. UR241-2 can serve as a ligand for target proteins for PROTAC, facilitating the development and design of PROTAC degraders for IRAK4. UR241-2 can be used in the research of acute myeloid leukemia .

HY-W900240

BMS-978299	IRAK	Inflammation/Immunology
BMS-978299 is an *IRAK4* inhibitor that can be used for the study of immune disorders .

HY-124995

BMS-986126	IRAK Toll-like Receptor (TLR) ERK NF-κB Interleukin Related	Inflammation/Immunology
BMS-986126 is a potent, selective, and orally active *IRAK4* inhibitor (IC₅₀ = 5.3 nM). BMS-986126 broadly inhibits MyD88-dependent signaling pathways. BMS-986126 demonstrates robust activity in the MRL/lpr and NZB/NZW murine models of lupus, inhibiting multiple pathogenic responses. BMS-986126 can be used for autoimmune diseases research, such as lupus erythematosus (SLE) .

HY-155132

IRAK4-IN-28	IRAK	Inflammation/Immunology
IRAK4-IN-28 (compound 42) is an orally active *IRAK4* inhibitor (IC₅₀=8.9 nM). IRAK4-IN-28 has binding affinity for IRAK4 with a Kd of 0.58 nM. IRAK4-IN-28 can be used in the research of inflammation and autoimmune diseases .

HY-155519

IRAK4-IN-26	IRAK	Inflammation/Immunology
IRAK4-IN-26 (Compound 21) is a *IRAK4* inhibitor (IC₅₀: 6.2 nM). IRAK4-IN-26 displays an oral bioavailability of 21%. IRAK4-IN-26 can be used for research of inflammatory and autoimmune disorders .

HY-143485

IRAK4-IN-9	IRAK	Inflammation/Immunology Cancer
IRAK4-IN-9 (compound 73) is a potent *IRAK4* inhibitor with an IC₅₀ of 1.5 nM. IRAK4-IN-9 blocks MyD88 dependent signaling. IRAK4-IN-9 has the potential for the research of inflammatory diseases, autoimmune diseases, and cancer .

HY-143231

IRAK4-IN-8	IRAK	Infection
IRAK4-IN-8 (VI-177) is a potent *IRAK4* inhibitor .

Cat. No.	Product Name		Classification

HY-145483

KT-474 1 Publications Verification KYM-001; PROTAC IRAK4 degrader-7		PROTAC Synthesis
KT-474 (KYM-001; PROTAC IRAK4 degrader-7) is an orally active PROTAC IRAK4 degrader with anti-tumor effects. KT-474 inhibits the cell cycle and induces apoptosis. KT-474 induces tumor regression in a xenograft model of MYD88-mutated ABC DLBCL. KT-474 is a click chemistry reagent, containing an alkyne group, which can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing azide groups .

Cat. No.	Product Name		Classification

HY-150741

ODN 2216 1 Publications Verification		CpG ODNs
ODN 2216 is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 interacts with TLR9 in the lysosomes of CD4 ⁺ T cells and activates feedback-dependent signaling pathways. ODN 2216 induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 not only induces the differentiation of CD4 ⁺ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 ⁺ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 is widely used in studies related to breast cancer and systemic lupus erythematosus .

HY-150741C

ODN 2216 sodium 1 Publications Verification		CpG ODNs
ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 sodium interacts with TLR9 in the lysosomes of CD4 ⁺ T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4 ⁺ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8 ⁺ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus .

HY-150750A

ODN M362 sodium		CpG ODNs
ODN M362 sodium is a TLR9 agonist that acts as a vaccine adjuvant. ODN M362 sodium activates mouse splenocytes, induces apoptosis in human hepatocellular carcinoma cells, upregulates proinflammatory cytokines in human hepatocellular carcinoma cells, and inhibits the proliferation of human hepatocellular carcinoma cells. ODN M362 sodium upregulates the expression of TLR9/TLR6, activates downstream signaling pathways via IRAK4 and IRF7, and strongly amplifies antigen-specific cellular immune responses to participate in innate immune activation. ODN M362 sodium can be used in research related to hepatocellular carcinoma and breast cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: